These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 28100259)

  • 1. Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism.
    El Bezawy R; De Cesare M; Pennati M; Deraco M; Gandellini P; Zuco V; Zaffaroni N
    J Hematol Oncol; 2017 Jan; 10(1):19. PubMed ID: 28100259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells.
    Cimino-Reale G; Gandellini P; Santambrogio F; Recagni M; Zaffaroni N; Folini M
    J Hematol Oncol; 2017 Jul; 10(1):140. PubMed ID: 28716051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.
    Mackiewicz M; Huppi K; Pitt JJ; Dorsey TH; Ambs S; Caplen NJ
    Breast Cancer Res Treat; 2011 Nov; 130(2):663-79. PubMed ID: 21814748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma.
    Belfiore A; Busico A; Bozzi F; Brich S; Dallera E; Conca E; Capone I; Gloghini A; Volpi CC; Cabras AD; Pilotti S; Baratti D; Guaglio M; Deraco M; Kusamura S; Perrone F
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-34a inhibits cell invasion and epithelial-mesenchymal transition via targeting AXL/PI3K/AKT/Snail signaling in nasopharyngeal carcinoma.
    Jiang C; Cheng Z; Jiang T; Xu Y; Wang B
    Genes Genomics; 2020 Aug; 42(8):971-978. PubMed ID: 32648233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance.
    Xiong R; Sun XX; Wu HR; Xu GW; Wang GX; Sun XH; Xu MQ; Xie MR
    Thorac Cancer; 2020 Jan; 11(1):156-165. PubMed ID: 31777195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma.
    El Bezawy R; Percio S; Ciniselli CM; De Cesare M; Colella G; Dugo M; Veneroni S; Doldi V; Martini S; Baratti D; Kusamura S; Verderio P; Deraco M; Gandellini P; Zaffaroni N; Zuco V
    Cancer Gene Ther; 2022 Oct; 29(10):1394-1404. PubMed ID: 35352023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An integrated approach of bioinformatic prediction and in vitro analysis identified that miR-34a targets
    Hajalirezay Yazdi S; Paryan M; Mohammadi-Yeganeh S
    Cell Mol Biol Lett; 2018; 23():51. PubMed ID: 30386383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
    De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
    Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine miR-34a-5p.
    Li YY; Tao YW; Gao S; Li P; Zheng JM; Zhang SE; Liang J; Zhang Y
    EBioMedicine; 2018 Oct; 36():209-220. PubMed ID: 30243489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.
    Ou WB; Hubert C; Corson JM; Bueno R; Flynn DL; Sugarbaker DJ; Fletcher JA
    Neoplasia; 2011 Jan; 13(1):12-22. PubMed ID: 21245936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts.
    De Cesare M; Sfondrini L; Pennati M; De Marco C; Motta V; Tagliabue E; Deraco M; Balsari A; Zaffaroni N
    J Transl Med; 2016 Jan; 14():25. PubMed ID: 26810896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling.
    Liu H; Deng H; Zhao Y; Li C; Liang Y
    J Exp Clin Cancer Res; 2018 Nov; 37(1):279. PubMed ID: 30463570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL.
    Li R; Shi X; Ling F; Wang C; Liu J; Wang W; Li M
    Tumour Biol; 2015 Sep; 36(9):7277-83. PubMed ID: 25895459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
    Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
    EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AXL regulates mesothelioma proliferation and invasiveness.
    Ou WB; Corson JM; Flynn DL; Lu WP; Wise SC; Bueno R; Sugarbaker DJ; Fletcher JA
    Oncogene; 2011 Apr; 30(14):1643-52. PubMed ID: 21132014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer.
    Mudduluru G; Ceppi P; Kumarswamy R; Scagliotti GV; Papotti M; Allgayer H
    Oncogene; 2011 Jun; 30(25):2888-99. PubMed ID: 21317930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
    Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
    Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of
    Pishkari S; Hadavi R; Koochaki A; Razaviyan J; Paryan M; Hashemi M; Mohammadi-Yeganeh S
    Horm Mol Biol Clin Investig; 2021 Mar; 42(3):265-271. PubMed ID: 33769725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
    Ma Y; Qin H; Cui Y
    Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.